Medulloblastoma ' Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Medulloblastoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Medulloblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medulloblastoma. Medulloblastoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Medulloblastoma.- A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Medulloblastoma pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Medulloblastoma.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

1. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Medulloblastoma ' Pipeline Review, H1 2013
Published on February 2013
Report Summary
Medulloblastoma ' Pipeline Review, H1 2013
Summary
Global Markets Direct's, 'Medulloblastoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline.
This report provides information on the therapeutic development for Medulloblastoma, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Medulloblastoma. Medulloblastoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets
Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.
Scope
- A snapshot of the global therapeutic scenario for Medulloblastoma.
- A review of the Medulloblastoma products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Medulloblastoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Medulloblastoma ' Pipeline Review, H1 2013 (From Slideshare) Page 1/6

2. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Medulloblastoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Medulloblastoma 7
Medulloblastoma Therapeutics under Development by Companies 9
Medulloblastoma Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Medulloblastoma Therapeutics ' Products under Development by Companies 15
Medulloblastoma Therapeutics ' Products under Investigation by Universities/Institutes 16
Companies Involved in Medulloblastoma Therapeutics Development 17
Eli Lilly and Company 17
Novartis AG 18
Lixte Biotechnology Holdings, Inc. 19
Stemline Therapeutics, Inc. 20
Archer Biosciences, Inc 21
Medulloblastoma ' Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
SL-301 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CST-102 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
erismodegib - Drug Profile 30
Product Description 30
Medulloblastoma ' Pipeline Review, H1 2013 (From Slideshare) Page 2/6

3. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Mechanism of Action 30
R&D Progress 30
erismodegib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
vismodegib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
vismodegib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ARC-100 + [temozolomide] - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LY-2940680 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
siomycin A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
carboplatin + vincristine sulfate + Radiation Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LB-102 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Medulloblastoma Therapeutics ' Drug Profile Updates 42
Medulloblastoma Therapeutics - Dormant Products 45
Medulloblastoma ' Product Development Milestones 46
Featured News & Press Releases 46
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
Medulloblastoma ' Pipeline Review, H1 2013 (From Slideshare) Page 3/6

4. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
List of Tables
Number of Products Under Development for Medulloblastoma, H1 2013 7
Products under Development for Medulloblastoma ' Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Eli Lilly and Company, H1 2013 17
Novartis AG, H1 2013 18
Lixte Biotechnology Holdings, Inc., H1 2013 19
Stemline Therapeutics, Inc., H1 2013 20
Archer Biosciences, Inc, H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Medulloblastoma Therapeutics ' Drug Profile Updates 42
Medulloblastoma Therapeutics ' Dormant Products 45
List of Figures
Number of Products under Development for Medulloblastoma, H1 2013 7
Products under Development for Medulloblastoma ' Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Discovery and Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27
Medulloblastoma ' Pipeline Review, H1 2013 (From Slideshare) Page 4/6

5. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Formats
Please select the product formats and the quantity you require.
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Medulloblastoma ' Pipeline Review, H1 2013
1 User License--USD 2 000.00 Quantity: _____
Site License--USD 4 000.00 Quantity: _____
Corporate License--USD 6 000.00 Quantity: _____
Medulloblastoma ' Pipeline Review, H1 2013 (From Slideshare) Page 5/6

6. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Customer signature:
Medulloblastoma ' Pipeline Review, H1 2013 (From Slideshare) Page 6/6